Focus on Risperidone

References

• Megens, A. A. (1994). Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacol. Berl., 114(1), 9–23.
   PubMed Web of Science ®Google Scholar
• Nyberg, S., Farde, L., Eriksson, L., Halldin, C. and Eriksson, B. (1993). 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacol. Berl., 110(3), 265–272.
   PubMed Web of Science ®Google Scholar
• Marder, S. R., Davis, J. M. and Chouinard, G. (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. UM. Psych., 58(12), 538–546.
   Google Scholar
• Davies, A., Adena, M. A., Keks, N. A., Catts, S. V., Lambert, T. and Schweitzer, I. (1998). Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. UM. Ther. 20(1), 58–71.
   Google Scholar
• Davies, A., Langley, P. C., Keks, N. A., Catts, S. V., Lambert, T. and Schweitzer, I. (1998). Risperidone versus haloperidol: II. Cost-effectiveness. UM. Then., 20(1), 196–213.
   Google Scholar
• Luchins, D. J., Klass, D., Hanrahan, P., Malan, R. and Harris, J. (1998). Alteration in the recommended dosing schedule for risperidone. Am. J. Psych., 155(3), 365–366.
   PubMed Web of Science ®Google Scholar
• Nair, N. P. (1998). Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. J. UM. Psycho-pharmacol., 18(2), 103–110.
   Web of Science ®Google Scholar
• Kirov, G. K., Murray, R. M., Seth, R. V. and Feeney, S. (1997). Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group. Acta. Psychiatr. Scand., 95(5), 439–443.
   PubMed Web of Science ®Google Scholar
• Schotte, A., Janssen, P. F. M. and Gommeren, W. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psycho-pharmacol., 124, 57–73.
   PubMed Web of Science ®Google Scholar
• Association of British Pharmaceutical Industries (1998). ABPI Compendium of Data Sheets. Summaries of Product Characteristics 1998–99. London, ABPI.
   Google Scholar
• Song, R (1997). Risperidone in the treatment of schizophrenia: a meta-analysis of random-ized controlled trials. J. Psychopharmacol. Oxf, 11(1), 65–71.
   PubMed Web of Science ®Google Scholar
• Buckley, F. et al. (1997). Aggression and schizophrenia: efficacy of risperidone. J. Am. Acad. Psychiatry Law., 25(2), 173–181.
   PubMed Web of Science ®Google Scholar
• Beck, N. C., Greenfield, S. R., Gotham, H., Menditto, A. A., Stuve, P. and Hemme, C. A. (1997). Risperidone in the management of violent, treatment-resistant schizo-phrenics hospitalized in a maximum security forensic facility. J. Am. Acad. Psychiatry Law, 25(4), 461–468.
   PubMed Web of Science ®Google Scholar
• De-Leon, O. A., Furmaga, K. M., Canterbury, A. L. and Bailey, L. G. (1997). Risperidone in the treatment of delusions of infestation. Int. J. Psychiatry Med., 27(4), 403–409.
   PubMed Web of Science ®Google Scholar
• Ghaemi, S. N., Sachs, G. S., Baldassano, C. R and Truman, C. J. (1997). Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can. J. Psychiatry, 42(2), 196–199.
   PubMed Web of Science ®Google Scholar
• Ghaemi, S. N. and Sachs, G. S.(1997). Long-term risperidone treatment in bipolar disorder: 6-month follow up. Int. UM. Psycho-pharmacol., 12(6), 333–338.
   PubMed Web of Science ®Google Scholar
• Saxena, S., Wang, D., Bystritsky, A. and Baxter, L. R. (1996). Risperidone augment-ation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry, 57(7), 303–306.
   PubMed Web of Science ®Google Scholar
• Stein, D. J., Bouwer, C., Hawkridge, S. and Emsley, R. A. (1997). Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J. UM. Psychiatry, 58(3), 119–122.
   Google Scholar
• Bruun, R. D. and Budman, C. L. (1996). Risperidone as a treatment for Tourette's syndrome. J. UM. Psychiatry, 57(1), 29–31.
   Google Scholar
• Muller Siecheneder, R, Muller, M. J., Hillert, A., Szegedi, A., Wetzel, H. and Benkert, O. (1998). Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J. Clin. Psychopharmacol., 18(2), 111–120.
   PubMed Web of Science ®Google Scholar
• Armenteros, J. L., Whitaker, A. H., Welikson, M., Stedge, J. and Gorman, J. (1997). Risperidone in adolescents with schizo-phrenia: an open pilot study. J. Am. Acad. Child Adolesc. Psych., 36(5), 694–700.
   PubMed Web of Science ®Google Scholar
• McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H. and Cohen, D. J. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J. Am. Acad. Child Adolesc. Psych., 36(5), 685–693.
   PubMed Web of Science ®Google Scholar
• Findling, R. L., Maxwell, K. and Wiznitzer, M. (1997). An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol. Bull., 33(1), 155–159.
   PubMed Web of Science ®Google Scholar
• Kopala, L. C. and Honer, W. G. (1997). The use of risperidone in severely demented patients with persistent vocalizations. Int. J. Geriatr. Psych., 12(1), 73–77.
   PubMed Web of Science ®Google Scholar
• Workman, R. H. Jr, Orengo, C. A., Bakey, A. A., Molinari, V. A. and Kunik, M. E. (1998). The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J. Neuropsych. Clin. Neurosci., 9(4), 594–597.
   Web of Science ®Google Scholar
• Katz, I. R., Jeste, D. V. and Mintzer, J. E. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. J. Clin. Psych., 60, 107–115.
   Web of Science ®Google Scholar
• Sipahimalani, A. and Masand, P. S. (1997). Use of risperidone in delirium: case reports. Ann. Clin. Psych., 9(2), 105–107.
   PubMedGoogle Scholar
• Furmaga, K. M. et al. (1997). Psychosis in medical conditions: response to risperidone. Gen. Hosp. Psych., 19(3), 223–228.
   PubMed Web of Science ®Google Scholar
• Singh, A. N., Golledge, H. and Catalan, J. (1997). Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J. Psychosom. Res., 42(5), 489–493.
   PubMed Web of Science ®Google Scholar
• Heykants, J., Huang, M. L., Mannens, G., Meuldermans, W., Snoeck, E., Van Beijsterveldt, L., Van Peer, A. and Woestenborghs, R. (1994). The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psych., 55 (Suppl), 13–17.
   Web of Science ®Google Scholar
• Borison, R.(1994). Risperidone:pharmacokinetics. J. Clin. Psych. Monograph, 12(2), 46–48.
   Google Scholar
• Huang, M. L., Van Peer, A., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A., Zylicz, Z., Visscher, H. W. and Jonkman, J. H. (1993). Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Phannacol. Ther., 54(3), 257–268.
   PubMed Web of Science ®Google Scholar
• Viale, G., Mechling, L., Maislin, G., Durkin, M., Engelhart, L. and Lawrence, B. J. (1997). Impact of risperidone on the use of mental health care resources. Psychiatr. Serv., 48(9), 1153–1159.
   PubMed Web of Science ®Google Scholar
• Franz, M., Lis, S., Pluddemann, K. and Gallhofer, B. (1997). Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br. J. Psych., 170, 422–425.
   PubMed Web of Science ®Google Scholar
• Chouinard, G. and Albright, P. S. (1997). Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J. Clin. Psychopharmacol., 17(4), 298–307.
   PubMed Web of Science ®Google Scholar
• Keks, N. A. (1997). Impact of newer anti-psychotics on outcomes in schizophrenia. Clin. Ther, 19(1), 148–158; discussion: pp. 126–127.
   PubMed Web of Science ®Google Scholar
• Kennedy, E., Song, F., Hunter, R., Clark, A. and Gilbody, S. (1999). Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 4. Update Software, Oxford.
   Google Scholar
• Allison, D. B., Mentore, J. L., Heo, M. et al (1999). Antipsychotic induced weight gain: a comprehensive research synthesis. Am. J. Psych., 156, 1686–1696.
   PubMed Web of Science ®Google Scholar
• Chouinard, G., Jones, B., Remington, G. et al. (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psycho-pharmacol., 13(1), 25–40.
   PubMed Web of Science ®Google Scholar
• Umbricht, D. and Kane, J. M. (1996). Medical complications of new antipsychotic drugs. Schizophr. Bull., 22(3), 475–483.
   PubMed Web of Science ®Google Scholar
• Kopala, L. C., Good, K. P. and Honer, W. G. (1997). Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J. Clin. Psychopharmacol., 17(4), 308–313.
   PubMed Web of Science ®Google Scholar
• Simpson, G. M. and Lindenmayer, J. P. (1997). Extrapyramidal symptoms in patients treated with risperidone. J. Clin. Psychopharmacol., 17(3), 194–201.
   PubMed Web of Science ®Google Scholar
• Zarate, C. A. Jr, Baldessarini, R. J., Siegel, A. J., Nakamura, A., McDonald, J., Muir Hutchinson, L. A., Cherkerzian, T. and Tohen, M. (1997). Risperidone in the elderly: a pharmacoepidemiologic study. J. Clin. Psych., 58(7), 311–317.
   Web of Science ®Google Scholar
• Kim, Y. K., Kim, L. and Lee, M. S. (1999). Risperidone and associated amenorrhea: a report of 5 cases. J. Clin. Psych., 60(5), 315–317.
   Web of Science ®Google Scholar
• Gazzola, L. R. and Opler, L. A. (1999). Return of menstruation after switching from risperidone to olanzapine [letter]. J. UM. Psychopharmacol., 18(6), 486–487.
   Web of Science ®Google Scholar
• Singer, S., Richards, C. and Boland, R. J. (1995). Two cases of risperidone-induced neuroleptic malignant syndrome [letter]. Am. J. Psych., 152(8), 1234.
   PubMed Web of Science ®Google Scholar
• Bonwick, R. J., Hopwood, M. J. and Morris, P. L. (1996). Neuroleptic malignant syn-drome and risperidone: a case report. Aust. N. Z. J. Psych., 30(3), 419–421.
   PubMed Web of Science ®Google Scholar
• Gleason, P. P. and Conigliaro, R. L. (1997). Neuroleptic malignant syndrome with risperidone. Pharmacother., 17(3), 617–621.
   PubMed Web of Science ®Google Scholar
• Bajjoka, I., Patel, T. and O'Sullivan, T. (1997). Risperidone-induced neuroleptic malignant syndrome. Ann. Emerg. Med., 30(5), 698–700.
   PubMed Web of Science ®Google Scholar
• Silberbauer, C. (1998). Risperidone-induced tardive dyskinesia. Pharmacopsych., 31(2), 68–69.
   PubMed Web of Science ®Google Scholar
• Tekell, J. L., Smith, E. A. and Silva, J. A. (1995). Prolonged erection associated with risperidone treatment [letter]. Am. J. Psych., 152(7), 1097.
   PubMed Web of Science ®Google Scholar
• Ravin, D. S. and Levenson, J. W. (1997). Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother., 31(7-8), 867–870.
   PubMed Web of Science ®Google Scholar
• Tooley, P. J. H. and Zuiderwijk, P. (1997). Drug safety: experience with risperidone. Adv. Ther, 14(5), 262–266.
   Web of Science ®Google Scholar
• Brown, K. (1993). Overdose of risperidone. Ann. Emerg. Med., 22(12), 1908–1910.
   PubMed Web of Science ®Google Scholar
• Springfield, A. C. and Bodiford, E. (1996). An overdose of risperidone. J. Anal. Toxicol., 20(3), 202–203.
   PubMed Web of Science ®Google Scholar
• Csernansky, J., Okamoto, A. and Brecher, M. (1999). Risperidone vs. haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders. A long-term double blind comparison. 54th Annual Scientific Convention of the Society for Biological Psychiatry, Washington, May, 1999.
   Google Scholar
• Masand, P. S. (1999). Relative weight gain among antipsychotics [letter]. J. Clin. Psych., 60, 706–707.
   Web of Science ®Google Scholar
• Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B. and Baumann, P. (1998). Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. J. Psych., 155(4), 499–504.
   PubMed Web of Science ®Google Scholar
• Still, D. J., Dorson, P. G., Crismon, M. L. and Pousson, C. (1996). Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr. Serv., 47 (12), 1382–1384.
   PubMed Web of Science ®Google Scholar
• Procyshyn, R. M. and Zerjav, S. (1998). Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin. Ther., 20, 1203–1217.
   PubMed Web of Science ®Google Scholar